Navigate the Sarepta Therapeutics and eteplirsen information pages
Stock symbol SRPT - formerly AVI BioPharma $AVII
Introduction
Webcasts and Events
Stock Analysis and Reporting
Eteplirsen Info
Media Reports and Patient Testimonials
Scientific and Medical Presentations
DMD and Competition
Infectious Disease Pipeline
Get first-hand perspective and education information from an inspiring family with two boys with DMD, plus learn how you can make a difference - visit www.DMDHero.com
Introduction
Webcasts and Events
Stock Analysis and Reporting
Eteplirsen Info
Media Reports and Patient Testimonials
Scientific and Medical Presentations
DMD and Competition
Infectious Disease Pipeline
Get first-hand perspective and education information from an inspiring family with two boys with DMD, plus learn how you can make a difference - visit www.DMDHero.com
Interview: December 2012
Bloomberg Briefs interviews SRPT CEO Chris Garabedian on plans for eteplirsen.
Webinar: November 14, 2012 4pm ET
Hosted by CureDuchenne and the FDA - CANCELLED
Webinar: October 23, 2012, 1pm ET
Hosted by Parent Project Muscular Dystrophy, featuring Sarepta CEO Chris Garabedian - details here.
World Muscle Society: October 13, 2012, 4am ET
Clinical trial presentation of 48 week data for eteplirsen in MD by Dr Jerry Mendell in Perth, Australia.
Earnings Conference Calls
Investor Webcasts |
|